Good morning, everyone, and how are you today? We would not be surprised to hear that many of you on this side of the pond may be a wee bit tired after tracking the extended drama over election results. After all, the right to vote is a good thing. And as our Bubbe taught us long ago, the only constant is change. So while you ponder what the future holds, please join us for a cup of stimulation and a quick look at the menu of tidbits we have provided. Hope your day goes well and, of course, do keep in touch. We enjoy the outreach …

After a pitched battle, former Celgene (CELG) chief executive Bob Hugin will not head to the U.S. Senate to represent New Jersey. The Democratic incumbent, Robert Menendez, prevailed in an especially nasty campaign in which Hugin was portrayed as a greedy pharma exec who repeatedly raised prices on a cancer drug and oversaw malfeasance because Celgene paid $280 million last year to settle a whistleblower lawsuit over allegedly illegal marketing tactics. For his part, Hugin ads reminded voters that Menendez was tried, unsuccessfully, for corruption. He also derided the “lies and mischaracterizations about the pharmaceutical industry. … We do such good things for all people around the world,” he told STAT.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy